ARA-290, also known as cibinetide, is an erythropoietin-derived peptide studied in tissue-protection models and small human trials of sarcoidosis-associated neuropathy.
Explore the research profileSubmit an unpaid laboratory order request for manual review. Availability and any pending amounts require confirmation.
Catalog quantities are not assay results.
Erythropoietin-derived signaling peptide
ARA-290 belongs to an 11-amino-acid peptide design derived from the exposed surface of erythropoietin's helix B. The design sought to separate tissue-protective signaling from the red-cell-production effects of intact erythropoietin. Structural similarity does not make the two molecules interchangeable.
This reference describes the published literature. Exact supplied form and chemical specifications require product-specific documentation. The studies are linked in Selected literature.
The proposed mechanism involves a receptor complex containing the erythropoietin receptor and the common beta receptor subunit CD131, often called the innate repair receptor. Preclinical work linked related helix-B-surface peptides to reduced injury responses without stimulating erythropoiesis in the tested systems.
Foundational studies examined helix-B-derived peptides in cell and rodent injury models, including ischemia and peripheral nerve injury. These experiments supplied a biological rationale for separating cytoprotection from red-cell stimulation, rather than proving a general repair effect in humans. [1]
A small placebo-controlled pilot trial enrolled people with sarcoidosis-associated small-fiber neuropathy. Some symptom measures favored ARA-290, while other pain and fatigue measures improved similarly in both groups. This mixed pattern is important when interpreting the early clinical signal. [2]
A later blinded study examined neuropathy symptoms and corneal small-nerve-fiber measures. An associated erratum corrected the numerical scaling of nerve-fiber-area calculations. Structural measurements remain distinct from demonstrating durable, generalized nerve regeneration or benefit in unrelated neuropathies. [3]
Study topics describe the cited models, not established benefits of this catalog material.
The cited human studies provide exploratory findings in a specific disease-associated neuropathy population. Their results support further investigation, but sample size, follow-up and endpoint selection limit broad conclusions. Mechanistic animal evidence should not be presented as an established human treatment effect.
Patient-reported outcomes can change with nonspecific trial effects, and imaging biomarkers need careful methodological interpretation. The corrected nerve-area calculations should be used when reviewing numerical results. Clinical study preparations do not validate WYZ material quality or establish equivalent pharmacology, exposure or safety.
Primary studies and clearly identified supporting sources. Each link opens the original record.
Helix-B-surface peptide design and separation from erythropoietic activity.
Small exploratory trial; not all symptom endpoints differed from placebo.
Read with 2016 arithmetic correction: https://pubmed.ncbi.nlm.nih.gov/28059429/; no uncorrected numeric nerve-area values reproduced.
Literature reviewed October 2026. This is a selected research overview, not an exhaustive systematic review. Published findings do not establish the identity, purity, sterility or suitability of any WYZ batch. For laboratory research only; not for human or veterinary use.
Final product specifications and product-specific storage instructions have not been supplied. Review the original documentation and your laboratory’s procedures before obtaining or using the material.
For qualified laboratory researchers. Not for human or veterinary use. Product information is not medical advice or a recommendation for personal use.
What to look for in a COAOther single compounds in the collection.
Metabolic Research
Retatrutide is a synthetic peptide studied for coordinated activation of three metabolic hormone receptors, with human research examining glucose regulation, appetite, body weight and liver fat.
Metabolic Research
MOTS-c is a mitochondrial-derived peptide studied in metabolic signaling and skeletal-muscle adaptation, with experimental interventions supported mainly by cell and animal evidence.
Dermal Research
GHK-Cu is a copper complex of glycyl-histidyl-lysine studied for its effects on extracellular-matrix production and remodeling in experimental tissue-repair systems.
